Zota Health Care Secures Product Registration in Cambodia

Zota Health Care Limited has successfully obtained a product registration licence for AZITOZ 500, an antibiotic containing Azithromycin Dihydrate, from Cambodia’s Ministry of Health. This milestone aligns with the company’s expansion strategy, paving the way for exports to the Cambodian market.

Regulatory Approval and Product Details

Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zota Health Care has officially disclosed the approval. The granted licence is valid for 5 years, with an option for renewal upon expiry. AZITOZ 500, classified as an antibiotic, will soon be introduced in Cambodia, enhancing the company’s global pharmaceutical footprint.

Strategic Expansion and Market Impact

With this approval, Zota Health Care is set to enter the Cambodian market, reinforcing its international presence. The planned exports of AZITOZ 500 will not only strengthen the company’s global outreach but also contribute to improved healthcare accessibility in Cambodia.

Zota Health Care Share Performance 

As of March 18, 2025, at 11:45 AM, The shares of Zota Health Care are trading at ₹789.95, reflecting a surge of around 2.09% from the previous closing price. Over the past month, the stock has registered a decline of 7.10%.

Conclusion

Securing the registration licence for AZITOZ 500 marks a significant step in Zota Health Care’s global expansion. With regulatory clearance in place, the company is poised to introduce its product to Cambodia, further strengthening its position in the pharmaceutical sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.